Context Therapeutics Inc.

NASDAQ:CNTX

Biotechnology

Healthcare
$0.69 +2.93%

+$0.02 today

Market cap
$63.67M
Beta
1.61
P/E (TTM)
-1.5
EPS (TTM)
-$0.42
52W Low $0.56High $3.62

Volume 1.71M

Average 1.16M

CNTX Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Context Therapeutics Inc.NASDAQ: CNTX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $36.11K rose 790.4% year over year, ahead of the +290.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 788.2% from the prior quarter. Over 3 fiscal years it compounded at +20.6% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +790.4% holds above the trailing-twelve-month pace of +290.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$36.11K+788.2% QoQ
Last fiscal yearDec 2025
$16.25K+49.4% YoY
LTMMar 2026
$48.3K+290.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+790.4%——
1 year+49.4%——
3-year CAGR+20.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
16.25K USD
Year-over-year change
+49.4%

Depreciation & Amortization vs competitors

How CNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +290.5% is the highest of 10, against a peer median of -11.2%.
  • Over three fiscal years its annual growth of +20.6% compares with a peer median of -11.9%.
CNTX Competitors
Depreciation & Amortization for CNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$7.09M USD-5.1%-15.4%4.5%
STTKShattuck Labs, Inc.LTM Mar 2026$3.64M USD-3.9%+6.3%364.3%
CLNNClene Inc.LTM Mar 2026$1.45M USD-11.2%+13.6%1079.1%
IMAImageneBio IncLTM Mar 2026$822K USD+129.6%+11.2%—
CNTBConnect Biopharma Holdings LimitedFY2025$704K USD+6.7%-11.9%1100.0%
IFRXInflaRx N.V.LTM Mar 2026€392.86K EUR-17.3%-11.1%1339.4%
OVIDOvid Therapeutics Inc.LTM Mar 2026$167K USD-73.0%-39.9%2.3%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$121K USD-27.5%-67.8%—
CNTXContext Therapeutics Inc.LTM Mar 2026$48.3K USD+290.5%+20.6%—
WHWKWhitehawk Therapeutics IncLTM Mar 2026$22K USD-88.5%-20.8%—
KLRSKalaris Therapeutics IncLTM Mar 2026$20K USD———
Peer median (excluding CNTX) —-11.2%-11.9%721.7%

Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development3.81M7.09M17.78M22.7M31.86M
Selling, General & Admin3.63M7.79M7.29M7.22M7.85M
Operating Expenses10.53M15.38M25.07M29.92M39.7M
Depreciation & Amortization09.27K12.04K10.88K16.25K
EBITDA(7.44M)(14.87M)(23.95M)(26.71M)(36.11M)
EBITDA Margin—————
Operating Income(10.53M)(15.38M)(25.07M)(29.92M)(39.7M)
Operating Margin—————
Interest Income64547.27K1.16M3.2M3.38M
Interest Expense64.24K547.27K000
Other Income / Expenses68.95K545.26K1.11M3.2M3.58M
Income Before Tax(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(10.46M)(14.84M)(23.96M)(26.73M)(36.12M)
Net Margin—————
EPS (Basic)(3.69)(0.93)(1.50)(0.46)(0.38)
EPS (Diluted)(3.69)(0.93)(1.50)(0.46)(0.38)
Weighted Avg Shares2.83M15.97M15.97M58.42M95.19M
Weighted Avg Shares (Diluted)2.83M15.97M15.97M58.42M95.19M

Context Therapeutics Inc.

NASDAQ:CNTX

Intrinsic Alpha fair value

Locked

Current Price

$0.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.